NCT01734252View on ClinicalTrials.gov

Argatroban in Critically Ill Patients With Heparin Resistance

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 29, 2012

Primary Completion Date

April 1, 2016

Study Completion Date

April 1, 2016

Conditions
Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance
Interventions
DRUG

Argatroban

Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min

Trial Locations (1)

6020

Medical University Innsbruck / Department for General and Surgical Intensive Care Medicine, Innsbruck

All Listed Sponsors
lead

Medical University Innsbruck

OTHER

NCT01734252 - Argatroban in Critically Ill Patients With Heparin Resistance | Biotech Hunter | Biotech Hunter